國立虎尾科技大學 |

Proteinkinase Inhibitors

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Proteinkinase Inhibitors/ edited by Stefan Laufer.
other author:	Laufer, Stefan.
Description:	VII, 256 p. 1 illus.online resource. :
Contained By:	Springer Nature eBook
Subject:	Medicinal chemistry. -
Online resource:	https://doi.org/10.1007/978-3-030-68180-7
ISBN:	9783030681807

Proteinkinase Inhibitors
Proteinkinase Inhibitors[electronic resource] /edited by Stefan Laufer. - 1st ed. 2021. - VII, 256 p. 1 illus.online resource. - Topics in Medicinal Chemistry,361862-247X ;. - Topics in Medicinal Chemistry,15.

ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.

This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.

ISBN: 9783030681807

Standard No.: 10.1007/978-3-030-68180-7doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

Proteinkinase Inhibitors
LDR:02623nam a22004095i 4500 001 1048569
003 DE-He213
005 20210817015520.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030681807 $9 978-3-030-68180-7
024 7 $a 10.1007/978-3-030-68180-7 $2 doi
035 $a 978-3-030-68180-7
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Proteinkinase Inhibitors $h [electronic resource] / $c edited by Stefan Laufer.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VII, 256 p. 1 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Topics in Medicinal Chemistry, $x 1862-247X ; $v 36
505 0 $a ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.
520 $a This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Proteins . $3 1253493
650 0 $a Bioorganic chemistry. $3 743635
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Protein Science. $3 782127
650 2 4 $a Bioorganic Chemistry. $3 677511
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Laufer, Stefan. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1051392
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030681791
776 0 8 $i Printed edition: $z 9783030681814
776 0 8 $i Printed edition: $z 9783030681821
830 0 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 15 $3 1253746
856 4 0 $u https://doi.org/10.1007/978-3-030-68180-7
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)